HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
February 21, 2025
-
REGULATORY Pfizer Pulls Japan NDA for Hemophilia Gene Therapy Beqvez as Program Called Off Globally
February 20, 2025
-
BUSINESS LTL Pharma Sees 30% Drop in Gaster Sales after New LLP Coverage Rollout
February 19, 2025
-
REGULATORY Espha’s Januvia Generic on Approval Roster towards June Listing
February 18, 2025
-
REGULATORY Japan to Approve EquMet Generics, More Copycats toward June Listing
February 17, 2025
-
REGULATORY J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27
February 14, 2025
-
BUSINESS Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
-
BUSINESS Cheplapharm Set to Expand LLP Deals to 20 APIs, Sees Opportunities Despite Headwinds
February 12, 2025
-
ORGANIZATION US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
February 10, 2025
-
BUSINESS Bain Picks Up Mitsubishi Tanabe for Over 500 Billion Yen
February 10, 2025
-
BUSINESS AstraZeneca Looks to Keep No.1 Spot in Japan Oncology Space, Driven by Bispecific Antibodies
February 7, 2025
-
BUSINESS Celltrion Set for 6 Biosimilar Filings in 2 Years, Sees Japanese Data Waiver as a Boon
February 6, 2025
-
REGULATORY Japan’s 1st Hemophilia B Gene Therapy Up for Panel Review on Feb. 19
February 6, 2025
-
COMMENTARY Companies Welcome Generic Drug Fund, but Fret Pricing and Regulations
February 5, 2025
-
BUSINESS Astellas to Revamp Management in April, Consolidate R&D Functions
February 5, 2025
-
ACADEMIA Medical Society Says “No” to Discontinuation of Theodur Despite Supply Struggle
February 5, 2025
-
REGULATORY PMD Act Set for Amendments Covering Issues Unaddressed over Past Decade: MHLW Official
February 4, 2025
-
BUSINESS Daiichi Sankyo Assigns COO Okuzawa as CEO from April
February 3, 2025
-
BUSINESS Julie Kim Tapped to Take Over Helm of Takeda in 2026
January 31, 2025
-
BUSINESS Takeda CEO Weber to Retire Next Year, Succeeded by US Head
January 30, 2025
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
